Immunoglobulin Market By Application, By Mode of Delivery, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

List of Tables

The immunoglobulin market is likely to experience a significant growth rate of 6.6% from 2023-2032 owing to increasing market demand of intravenous segment - Allied Market Research

The growth of the immunoglobulin market is primarily propelled by the escalating prevalence of life-threatening diseases, including immunodeficiency disorders, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Idiopathic Thrombocytopenic Purpura (ITP), and others. The increasing aging population, vulnerable to infections, further contributes to market expansion. Additionally, the expanding applications of immunoglobulins in treating autoimmune diseases and neurologic disorders play a pivotal role in driving market growth. These key factors collectively underscore the crucial role of immunoglobulins in addressing a diverse range of medical conditions, fueling innovation, and meeting the healthcare needs of a broad patient demographic.

Furthermore, the presence of reimbursement policies is further anticipated to potentially drive the market growth. Reimbursement policies play a pivotal role in facilitating patient access to immunoglobulin therapies by alleviating the financial burden associated with high treatment costs. As these policies provide financial support and coverage for immunoglobulin treatments, they enhance affordability for patients, making therapies more accessible and attractive for healthcare providers. Furthermore, reimbursement policies incentivize pharmaceutical companies to invest in research, development, and production, fostering innovation in the field. For instance, Octapharma USA received Medicare Part B approval of cutaquig 16.5% for adult primary immunodeficiency patients. In addition, owing to the approval, Octapharma increased its production of cutaquig by more than 45%, to meet patient needs. Thus, the presence of reimbursement policies not only benefit the patients but also incentivize pharmaceutical companies, thereby driving the market growth.

The immunoglobulin market is segmented on the basis of application, mode of delivery, distribution channel, and region. On the basis of application, the market is classified into primary immunodeficiency disease, chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, Guillain-Barre syndrome and others. On the basis of mode of delivery, the market is categorized into intravenous, subcutaneous and intramuscular. The intravenous segment is further divided into 5% concentration, 10% concentration, and others. The subcutaneous segment is further divided into 16.5% concentration, 20% concentration, and others. Depending on distribution channel, the market is fragmented into hospital pharmacy, drug stores & retail pharmacy, and others. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The major key players that operate in the global immunoglobulin market are CSL, Kedrion, SpA, Takeda Pharmaceutical Company Limited, Bio Products Laboratory Limited, Taibang Biological Group Co., Ltd Grifols, S.A., Octapharma AG, Pfizer Inc., LFB Group, and Prothya Biosolutions.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the immunoglobulin market analysis from 2022 to 2032 to identify the prevailing immunoglobulin market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the immunoglobulin market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global immunoglobulin market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Application

Primary Immunodeficiency Disease
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Myasthenia Gravis
Multifocal Motor Neuropathy
Idiopathic Thrombocytopenic Purpura (ITP)
Guillain-Barre Syndrome
Others

By Mode of Delivery

Intravenous
- Type
- 5% concentration
- 10% concentration
- Others
Subcutaneous
- Type
- 16.5% concentration
- 20% concentration
- Others
Intramuscular

By Distribution Channel

Hospital pharmacy
Drug stores and retail pharmacy
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

CSL
Kedrion, SpA
Bio Products Laboratory Limited
Grifols, S.A.
Octapharma AG
Pfizer Inc.
Prothya Biosolutions
Takeda Pharmaceutical Company Limited
Taibang Biological Group Co., Ltd.
LFB Group

Product Code: A02254

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in prevalence of immunodeficiency diseases
  - 3.4.1.2. Increase in adoption of immunoglobulin
  - 3.4.1.3. Growth in geriatric population
- 3.4.2. Restraints
  - 3.4.2.1. Dependence on Plasma Supply
  - 3.4.2.2. High treatment cost
- 3.4.3. Opportunities
  - 3.4.3.1. Growing regulatory support

CHAPTER 4: IMMUNOGLOBULIN MARKET, BY APPLICATION

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Primary Immunodeficiency Disease
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Myasthenia Gravis
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Multifocal Motor Neuropathy
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
4.6. Idiopathic Thrombocytopenic Purpura (ITP)
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country
4.7. Guillain-Barre Syndrome
- 4.7.1. Key market trends, growth factors and opportunities
- 4.7.2. Market size and forecast, by region
- 4.7.3. Market share analysis by country
4.8. Others
- 4.8.1. Key market trends, growth factors and opportunities
- 4.8.2. Market size and forecast, by region
- 4.8.3. Market share analysis by country

CHAPTER 5: IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Intravenous
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.2.4. Intravenous Immunoglobulin Market by Type
5.3. Subcutaneous
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- 5.3.4. Subcutaneous Immunoglobulin Market by Type
5.4. Intramuscular
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital pharmacy
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Drug stores and retail pharmacy
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Others
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: IMMUNOGLOBULIN MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Application
- 7.2.3. Market size and forecast, by Mode of Delivery
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Market size and forecast, by Application
  - 7.2.5.1.2. Market size and forecast, by Mode of Delivery
  - 7.2.5.1.3. Market size and forecast, by Distribution Channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Market size and forecast, by Application
  - 7.2.5.2.2. Market size and forecast, by Mode of Delivery
  - 7.2.5.2.3. Market size and forecast, by Distribution Channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Market size and forecast, by Application
  - 7.2.5.3.2. Market size and forecast, by Mode of Delivery
  - 7.2.5.3.3. Market size and forecast, by Distribution Channel
7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Application
- 7.3.3. Market size and forecast, by Mode of Delivery
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Market size and forecast, by Application
  - 7.3.5.1.2. Market size and forecast, by Mode of Delivery
  - 7.3.5.1.3. Market size and forecast, by Distribution Channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Market size and forecast, by Application
  - 7.3.5.2.2. Market size and forecast, by Mode of Delivery
  - 7.3.5.2.3. Market size and forecast, by Distribution Channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Market size and forecast, by Application
  - 7.3.5.3.2. Market size and forecast, by Mode of Delivery
  - 7.3.5.3.3. Market size and forecast, by Distribution Channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Market size and forecast, by Application
  - 7.3.5.4.2. Market size and forecast, by Mode of Delivery
  - 7.3.5.4.3. Market size and forecast, by Distribution Channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Market size and forecast, by Application
  - 7.3.5.5.2. Market size and forecast, by Mode of Delivery
  - 7.3.5.5.3. Market size and forecast, by Distribution Channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Market size and forecast, by Application
  - 7.3.5.6.2. Market size and forecast, by Mode of Delivery
  - 7.3.5.6.3. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Application
- 7.4.3. Market size and forecast, by Mode of Delivery
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Market size and forecast, by Application
  - 7.4.5.1.2. Market size and forecast, by Mode of Delivery
  - 7.4.5.1.3. Market size and forecast, by Distribution Channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Market size and forecast, by Application
  - 7.4.5.2.2. Market size and forecast, by Mode of Delivery
  - 7.4.5.2.3. Market size and forecast, by Distribution Channel
  - 7.4.5.3. India
  - 7.4.5.3.1. Market size and forecast, by Application
  - 7.4.5.3.2. Market size and forecast, by Mode of Delivery
  - 7.4.5.3.3. Market size and forecast, by Distribution Channel
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Market size and forecast, by Application
  - 7.4.5.4.2. Market size and forecast, by Mode of Delivery
  - 7.4.5.4.3. Market size and forecast, by Distribution Channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Market size and forecast, by Application
  - 7.4.5.5.2. Market size and forecast, by Mode of Delivery
  - 7.4.5.5.3. Market size and forecast, by Distribution Channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Market size and forecast, by Application
  - 7.4.5.6.2. Market size and forecast, by Mode of Delivery
  - 7.4.5.6.3. Market size and forecast, by Distribution Channel
7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Application
- 7.5.3. Market size and forecast, by Mode of Delivery
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Market size and forecast, by Application
  - 7.5.5.1.2. Market size and forecast, by Mode of Delivery
  - 7.5.5.1.3. Market size and forecast, by Distribution Channel
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Market size and forecast, by Application
  - 7.5.5.2.2. Market size and forecast, by Mode of Delivery
  - 7.5.5.2.3. Market size and forecast, by Distribution Channel
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Market size and forecast, by Application
  - 7.5.5.3.2. Market size and forecast, by Mode of Delivery
  - 7.5.5.3.3. Market size and forecast, by Distribution Channel
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Market size and forecast, by Application
  - 7.5.5.4.2. Market size and forecast, by Mode of Delivery
  - 7.5.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. CSL
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
9.2. Kedrion, SpA
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
9.3. Takeda Pharmaceutical Company Limited
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
9.4. Bio Products Laboratory Limited
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
9.5. Prothya Biosolutions
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
9.6. Taibang Biological Group Co., Ltd.
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
9.7. Grifols, S.A.
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
9.8. Octapharma AG
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
9.9. LFB Group
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
9.10. Pfizer Inc.
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance